BRIEF—Micreos raises 30 million euros with claim that it will 'replace antibiotics'

Dutch biotech Micreos has secured 30 million euros in funding to advance the development of its endolysin technology, which it claims is ‘set to replace antibiotics’.

Proceeds from the financing are earmarked for the clinical development program of endolysin XZ.700 and the US launch of the company’s over-the-counter Gladskin product for eczema.

Micreos underlines that endolysins have the ability to target only unwanted bacteria while preserving the microbiome and to kill antibiotic resistant strains of bacteria, and says that the emergence of resistance against endolysins is not expected.

The firm argues that endolysin technology opens a new therapeutic window for treatment of chronic inflammatory conditions, such as atopic dermatitis and persistent wound infections, including those caused by MRSA.